Jean-Michel Paillarse

Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease

Florian Plaza Oñate, Célia Chamignon, Sebastian D. Burz et al. · International Journal of Molecular Sciences · 2023 · 89 citations · Full text

Life Sciences, Microbiology, Pathobiology +17

Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD)

Sebastian D. Burz, Magali Monnoye, Catherine Philippe et al. · Microorganisms · 2021 · 65 citations · Full text

Life Sciences, Biochemistry, Microbiology +15

Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease

Walter Reinisch, Xavier Hébuterne, Anthony Buisson et al. · Journal of Gastroenterology and Hepatology · 2022 · 28 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

P568 An open-label, multicenter, phase ib, pharmacokinetic (pk) and safety study of a fimh blocker, Sibofimloc (TAK-018/EB8018), in patients with Crohn’s disease (CD)

Walter Reinisch, Xavier Hébuterne, Anthony Buisson et al. · Journal of Crohn s and Colitis · 2020 · 12 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.

Éric Baudin, Camilo Jiménez, Salvatore Grisanti et al. · Journal of Clinical Oncology · 2022 · 10 citations

Medicine, Immunology, Oncology +17